Literature DB >> 15037160

Determinants of F2-isoprostane biosynthesis and inhibition in man.

Giovanni Davì1, Angela Falco, Carlo Patrono.   

Abstract

Several cardiovascular risk factors are characterized by the coexistence of low-grade inflammation, enhanced oxidative stress and lipid peroxidation. It has been hypothesized that F2-isoprostanes, a product of in vivo lipid peroxidation, may transduce the effects of metabolic and hemodynamic abnormalities into increased cardiovascular risk. Thus, the formation of these compounds, including urinary 8-iso-Prostaglandin (PG) F2alpha, has been investigated in clinical settings putatively associated with oxidant stress. Enhanced lipid peroxidation together with increased in vivo platelet activation have been found in association with the major cardiovascular risk factors. Thus, F2-isoprostanes may transduce the effects of oxidant stress associated with complex metabolic disorders into specialized forms of cellular activation. In particular, the low-grade inflammatory state characterizing metabolic disorders such as obesity, hypercholesterolemia, type 2 diabetes mellitus, and homozygous homocystinuria may be the primary trigger of thromboxane-dependent platelet activation mediated, at least in part, through enhanced lipid peroxidation. Moreover, oxidative stress may promote endothelial dysfunction through increased production of reactive oxygen species that inactivate nitric oxide. Accumulation and activation of leukocytes plays a key role in atherosclerosis and its complications. Interestingly, neutrophil adhesion induced by minimally modified low-density lipoproteins is mainly mediated by F2-isoprostanes. Although epidemiological studies suggest an inverse relationship between antioxidant vitamin intake and cardiovascular disease, several clinical trials have obtained conflicting results on the effects of vitamin E supplementation on the risk of cardiovascular events. On the other hand, the use of F2-isoprostane formation as a biochemical end-point for dose-finding studies of vitamin E supplementation has helped clarifying the unique features of its pharmacodynamic effects on lipid peroxidation. This information could be extremely valuable in the selection of the appropriate patient subgroups that may benefit from antioxidant interventions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037160     DOI: 10.1016/j.chemphyslip.2003.10.001

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  14 in total

Review 1.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

2.  Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study.

Authors:  Matteo Cesari; Stephen B Kritchevsky; Barbara Nicklas; Alka M Kanaya; Paola Patrignani; Stefania Tacconelli; Gregory J Tranah; Gianni Tognoni; Tamara B Harris; Raffaele Antonelli Incalzi; Anne B Newman; Marco Pahor
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-01       Impact factor: 6.053

3.  Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.

Authors:  Tyler J Gluckman; Rhondalyn C McLean; Steven P Schulman; Thomas S Kickler; Edward P Shapiro; John V Conte; Kathleen W McNicholas; Jodi B Segal; Jeffrey J Rade
Journal:  J Am Coll Cardiol       Date:  2011-03-01       Impact factor: 24.094

Review 4.  The isoprostanes--25 years later.

Authors:  Ginger L Milne; Qi Dai; L Jackson Roberts
Journal:  Biochim Biophys Acta       Date:  2014-10-30

Review 5.  Inflammation, insulin resistance, and obesity.

Authors:  Patrizia Ferroni; Stefani Basili; Angela Falco; Giovanni Davì
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

6.  The association of serum trans-nonachlor levels with atherosclerosis.

Authors:  Lee C Mangum; Lauren H Mangum; Janice E Chambers; Matthew K Ross; Edward C Meek; Robert W Wills; J Allen Crow
Journal:  J Toxicol Environ Health A       Date:  2016-03-08

7.  Elevated plasma F2-isoprostane levels in schizophrenia.

Authors:  Ellen E Lee; Lisa T Eyler; Owen M Wolkowitz; Averria Sirkin Martin; Chase Reuter; Helena Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-06-16       Impact factor: 4.939

8.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

9.  Lipid peroxidation and depressed mood in community-dwelling older men and women.

Authors:  Yuri Milaneschi; Matteo Cesari; Eleanor M Simonsick; Nicole Vogelzangs; Alka M Kanaya; Kristine Yaffe; Paola Patrignani; Andrea Metti; Stephen B Kritchevsky; Marco Pahor; Luigi Ferrucci; Brenda W J H Penninx
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

10.  Relationship of urinary isoprostanes to prostate cancer occurrence.

Authors:  Magdalena Brys; Agnieszka Morel; Ewa Forma; Anna Krzeslak; Jacek Wilkosz; Waldemar Rozanski; Beata Olas
Journal:  Mol Cell Biochem       Date:  2012-09-16       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.